Specific immunotherapy: One size does not fit all

被引：33

作者：

Genain, CP ^{[1
]}

Zamvil, SS ^{[1
]}

机构：

[1] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA

来源：

NATURE MEDICINE | 2000年 / 6卷 / 10期

关键词：

D O I：

10.1038/80424

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Two clinical trials testing an altered peptide ligand (APL) in multiple sclerosis report seemingly contradictory results. Immunologic analysis shows that the biological effects of APLs extend far beyond what was initially envisioned, raising important issues for the development of this type of therapy (pages 1167-1175 & 1176-1182).

引用

页码：1098 / 1100

页数：3

共 22 条

[1] Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking
Aharoni, R
Teitelbaum, D
Arnon, R
Sela, M
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (02) : 634 - 639
[2] Complementary mutations in an antigenic peptide allow for crossreactivity of autoreactive T-cell clones
Ausubel, LJ
Kwan, CK
Sette, A
Kuchroo, V
Hafler, DA
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (26) : 15317 - 15322
[3] Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand
Bielekova, B
Goodwin, B
Richert, N
Cortese, I
Kondo, T
Afshar, G
Gran, B
Eaton, J
Antel, J
Frank, JA
McFarland, HF
Martin, R
[J]. NATURE MEDICINE, 2000, 6 (10) : 1167 - 1175
[4] Late complications of immune deviation therapy in a nonhuman primate
Genain, CP
Abel, K
Belmar, N
Villinger, F
Rosenberg, DP
Linington, C
Raine, CS
Hauser, SL
[J]. SCIENCE, 1996, 274 (5295) : 2054 - 2057
[5] Identification of autoantibodies associated with myelin damage in multiple sclerosis
Genain, CP
Cannella, B
Hauser, SL
Raine, CS
[J]. NATURE MEDICINE, 1999, 5 (02) : 170 - 175
[6] Gran B, 1999, ANN NEUROL, V45, P559, DOI 10.1002/1531-8249(199905)45:5<559::AID-ANA3>3.0.CO
[7] 2-Q
[8] Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial
Kappos, L
Comi, G
Panitch, H
Oger, J
Antel, J
Conlon, P
Steinman, L
[J]. NATURE MEDICINE, 2000, 6 (10) : 1176 - 1182
[9] LUCHINETTI CF, 1996, BRAIN PATHOL, V6, P259
[10] Madrenas J, 1996, Semin Immunol, V8, P83, DOI 10.1006/smim.1996.0011

← 1 2 3 →